Physician profile
Benny Wang
NPI 1447348164
$48,841.98
in general payments reported to CMS, 2019-2025
80 companies · $5,381 in 2025
The $5,381 reported for 2025 was more than what 85% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,486 · 2020: $14K · 2021: $9,375 · 2022: $6,439 · 2023: $4,712 · 2024: $5,304 · 2025: $5,381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,397.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $11,797.65 | 2019-2022 | |
| Abbvie INC. | $8,860.77 | 2019-2025 | Ubrelvy, Duopa, Botox |
| Novartis Pharmaceuticals Corporation | $1,873.90 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $1,635.08 | 2019-2025 | |
| Lundbeck LLC | $1,512.20 | 2020-2025 | Vyepti, Rexulti |
| Emd Serono, INC. | $1,375.39 | 2019-2025 | Mavenclad |
| Ucb, INC. | $1,339.84 | 2019-2025 | Fintepla, Briviact, Rystiggo |
| Teva Pharmaceuticals USA, INC. | $1,193.70 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Eisai INC. | $1,030.26 | 2019-2025 | |
| Biogen, INC. | $965.19 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Neurocrine Biosciences, INC. | $918.58 | 2019-2025 | Ingrezza, Ongentys |
| Takeda Pharmaceuticals U.S.A., INC. | $787.37 | 2021-2025 | Hyqvia, Gammagard |
| Genentech USA, INC. | $767.18 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Harmony Biosciences LLC | $764.34 | 2020-2025 | Wakix |
| Sunovion Pharmaceuticals INC. | $722.19 | 2019-2022 |
Show all 80 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benny Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.